Key result
Finerenone and ns-MRAs reduce residual kidney and CV risk in DKD.
Why the study?
Unmet cardiorenal risk persists in patients with type 2 diabetes and chronic kidney disease under standard renin-angiotensin system therapy.
Nonsteroidal MRAs, particularly finerenone, are emerging as key guideline-endorsed therapies for reducing cardiorenal risk in diabetic kidney disease.
Answers are grounded in this paper and cite their sources.
Prompts finerenone integration into T2D-CKD care to reduce cardiorenal events; extends RCT data into guideline-directed practice.
Nonsteroidal mineralocorticoid receptor antagonists (ns-MRA) have emerged as a key therapeutic option for patients with type 2 diabetes and chronic kidney disease, addressing the unmet cardiorenal risk that persists under standard renin-angiotensin system therapy. Finerenone, the most extensively studied ns-MRA, has demonstrated significant reductions in kidney and cardiovascular outcomes across a broad spectrum of CKD severity, with a favorable safety profile. Recent guideline recommendations endorse ns-MRAs in patients with persistent albuminuria despite optimized standard therapy. Moreover, combination strategies with sodium-glucose cotransporter 2 inhibitors show additive benefits, supporting a multi-targeted treatment approach. This review summarizes the pathophysiological rationale, clinical evidence, safety considerations, and combination strategies involving ns-MRAs in contemporary diabetic kidney disease management.
No takes yet. Share an insight, caveat, or question.
Jeong et al. (2026) conducted a review in Diabetic kidney disease. Nonsteroidal mineralocorticoid receptor antagonists vs. Standard therapy was evaluated. Nonsteroidal mineralocorticoid receptor antagonists, particularly finerenone, reduce residual kidney and cardiovascular risk in patients with diabetic kidney disease and are recommended as a core component of guideline-directed therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: